![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium.
Lead Product(s): Tenapanor Hydrochloride
Therapeutic Area: Gastroenterology Product Name: Ibsrela
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
IBSRELA®(tenapanor) is the first and only NHE3 Inhibitor FDA approved for the treatment of IBS-C in adults, reported 41% improvement in quality of life score from baseline to end of treatment, and vast majority of patients reported satisfaction with treatment.
Lead Product(s): Tenapanor Hydrochloride
Therapeutic Area: Gastroenterology Product Name: Ibsrela
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022